Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV
Gilead Sciences, Inc. (NASDAQ: GILD) today announced it is providing $17.6 million in grants to 30 organizations in the United States through the Gilead HIV Age Positively initiative. This effort aims to enhance the lives of individuals aging with HIV by focusing in three priority areas: improving care coordination, increasing resources for better well-being, and educating and informing policies that impact people living and aging with HIV. Estimates suggest that by 2030, more than 80 percent of people living with HIV will face at least one age-related medical condition, compared to just 29 percent in 2010.
“Community partners who work tirelessly to improve the lives of people living with HIV inspire us all,” said Amy Flood, Senior Vice President of Public Affairs at Gilead. “Gilead understands science alone is not enough to help people lead longer, healthier lives. That’s why we work together with advocates, healthcare providers and community organizations to identify the unique challenges people aging with HIV experience and dedicate resources to maximize impact in communities across the country.”
The HIV Age Positively grantees include longtime advocacy organizations, who are now better equipped to provide life-saving services to their communities, as well as newer organizations that add to the overall effort to strengthen care and services for this growing population. Each grantee was selected for their unique ability to articulate interventions that have the potential to transform the quality of life for people aging with HIV.
“Anyone who lived through the 1980s and ‘90s remembers the generation of Americans we lost to the HIV epidemic and the heroic work this community has done together to increase the life expectancy of people living with HIV," said Kelsey Louie, Chief Executive Officer, Gay Men’s Health Crisis. "As they have in the past, Gilead brought experts together, listened to what our community needed and identified the organizations best equipped to tackle specific problems. Funding from HIV Age Positively is going to help long-term survivors combat loneliness, obtain access to the resources and support they need and create better, more personalized healthcare. Everyone deserves to live a long and healthy life and this program is going to help make that possible for countless people living and aging with HIV."
Aging people living with HIV face a unique set of challenges, and healthcare providers and the broader community of allies need additional resources to meet their needs. As part of the HIV Age Positively effort, Gilead convened an advisory board of experts with deep insights into the subject of aging with HIV.
“The advisory board created a space for leaders to come together and address these unmet needs of people aging with HIV,” said Stephen Karpiak, Ph.D., Senior Director of Research at ACRIA Center on HIV and Aging at GMHC, and a member of the advisory board. “By spotlighting and uplifting potential interventions, we aim to shine a bright new light on the too often forgotten and marginalized community of people aging with HIV: the challenges they face, the resources they need and the support they deserve.”
The advisory board members included healthcare providers, researchers and community advocates from AIDS Project Los Angeles (APLA), Test Positive Awareness Network (TPAN), the University of Pittsburgh, Boston University, ACRIA, University of California, San Diego, HTW Campaign, SAGE and the HIV Vaccine Trials Network.
This group determined that addressing the interrelated challenges within our healthcare system and the general HIV community, like stigma, loneliness and better coordination of care, is essential in reaching a viable solution to these challenges.
Recipient grantees include:
- Abounding Prosperity – Dallas, TX
- The AIDS Institute, Inc. – Nationwide
- AIDS Project – New Haven, CT
- American Indian Community House, Inc. – Nationwide
- APLA Health & Wellness – California Statewide
- The Association of Nurses in AIDS Care – Nationwide
- Borrego Community Health Foundation – Southern California
- Cascade AIDS Project – Oregon and Southwest Washington
- Center for Health Justice, Inc. – Los Angeles, CA
- Community Healthcare Network, Inc. – New York, NY
- Family Health Centers of San Diego, Inc. – San Diego, CA
- Gay Men’s Health Crisis – Nationwide
- HealthHIV – Nationwide
- Hektoen Institute for Medical Research – Chicago, IL
- Legal Aid Service of Broward County, Inc. – Broward County, FL
- Montefiore Medical Center – New York, NY
- My Brother’s Keeper – Mississippi (Statewide)
- New Orleans Advocates for GLBT Elders (NOAGE) – New Orleans, LA
- Professional Association of Social Workers in HIV & AIDS – Nationwide
- Project Open Hand – San Francisco, CA
- Regents of the University of California at San Diego – San Diego, CA
- SAGE – Nationwide
- San Francisco AIDS Foundation – San Francisco, CA
- Shanti Project, Inc. – San Francisco, CA
- Thrive SS, Inc. – Nationwide
- Test Positive Awareness Network, Inc.– Chicago, IL
- University of California, San Francisco – San Francisco, CA
- University of Maryland Baltimore Foundation Inc. – Baltimore, MD
- Us Helping Us - People Into Living, Inc. – Washington, DC
- Washington Hospital Center Corporation – Washington, DC
For more information visit: https://www.gilead.com/purpose/partnerships-and-community/hiv-age-positively
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 18:55:00 EET | Tiedote
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u
Logicor Announces Results for Year Ended 31 December 201822.3.2019 17:29:00 EET | Tiedote
Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of
Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 17:15:00 EET | Tiedote
Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha
Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation22.3.2019 16:00:00 EET | Tiedote
Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190322005013/en/ Trueman Man Clinic Network has been successfully completed the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation). The SWITCH Premature Ejaculation Surgery (SWITCH operation) developed in 2010 by Dr. Yang, the chief director of the Trueman Man Clinic Network, can reduce the side effects of penile neurectomy and maintain the stable reduction of the glans sensation. The Trueman Man Clinic Network is the leading hospitals for male enhancement surgeries in Korea consists of 11 clinics, with 16 doctors working. As of 2019, more than 43,000 man clinic surgeries have been performed. (Photo: Business Wire) The Trueman Man Clinic Network is the leading hospitals for m
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible22.3.2019 14:22:00 EET | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX®▼ (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). “Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical Affairs, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “We are incredibly grateful to the patients and investigators who participated in the MAIA clinical trial programme and look forward to working closely with the regulatory authorities to secure approval of this new combination.” The submission is supported by data from the Phase 3 MAIA (MMY3008) study, which were presented at the 60th Annual Meeting of the American
Bartek Ingredients Expands Leadership Team22.3.2019 01:35:00 EET | Tiedote
Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme